Imparica

Argus’ Jacob Kilstein believes Zoetis Inc (NYSE: ZTS) has been benefiting from a “lack of generic competition in the animal drug space.” Kilstein maintains a Buy rating on the company, while raising the price target from $54 to $58. Benefiting From Animal Drug Space The analyst...